Explore evidence

1.6 %Diabetes prevalence was 1.6% in Rwanda in 2012.

Rwandadiabète (non précisé)observed 2012HAL · Unilimdocument of 120 observations

26 confirmed_casesRwanda reported 26 confirmed mpox cases and zero deaths among confirmed cases in 2024.

Rwandampoxobserved 2024Africa CDCdocument of 74 observations

2.1 %In Rwanda, the HIV testing yield increased from 2.1% to 6.3%.

RwandaVIH/sidapublished 2021BMC health services researchPubMeddocument of 5 observations

Five countries — DRC, Rwanda, Uganda, Central African Republic, and Nigeria — are currently vaccinating against mpox.

Nigeria · Ouganda · RDC · RwandampoxAfrica CDCdocument of 72 observations

85,400 vaccine_doses85,400 Mpox vaccine doses were airlifted and delivered to Rwanda, Côte d’Ivoire, the Central African Republic, and Sierra Leone.

Rwanda · Sierra LeonempoxAfrica CDCdocument of 72 observations

No deaths have been reported in Eastern DRC or in the newly affected countries of Burundi, Rwanda, Kenya, and Uganda, where outbreaks are linked to clade Ib.

Burundi · Kenya · Ouganda · Rwandaclade Ib · mpoxAfrica CDCdocument of 4 observations

3 individualsSerology tests identified three individuals seropositive for immunoglobulin G and immunoglobulin M in the Marburg virus disease outbreak in Rwanda.

RwandaMarburg virus diseasepublished 2025Nature medicineeurope_pmcdocument of 4 observations

The ongoing outbreak of Marburg virus disease in Rwanda has shown the lowest fatality rate historically.

RwandaMarburg virus diseasepublished 2025Nature medicineeurope_pmcdocument of 4 observations

90 %Rwanda achieved a HPV vaccination coverage rate exceeding 90% by the end of the first year of its program in 2011.

Rwandainfection à HPVobserved 2011Africa CDCdocument of 51 observations

5,800 vaccine_doses5,800 MVA-BN vaccine doses were delivered to Rwanda for Mpox.

RwandampoxAfrica CDCdocument of 72 observations

In Rwanda, the R561H Pfk13 mutation has been associated with delayed parasite clearance.

Rwandapaludismepublished 2021International journal for parasitology. Drugs and drug resistanceeurope_pmcdocument of 4 observations

21.7 %In Rwanda, the partner testing acceptance rate increased from 21.7% to 48.2%, resulting in an increase in HIV testing yield from 2.1% to 6.3%.

RwandaVIH/sidapublished 2021BMC health services researchPubMeddocument of 5 observations

55 %Over 55% of expected cervical cancers are diagnosed in Rwanda.

Rwandacancer du col de l'utérusAfrica CDCdocument of 52 observations

92 %Rwanda achieved 92% HPV vaccination coverage.

Rwandainfection à HPVAfrica CDCdocument of 52 observations

Cervical cancer is the second most prevalent cancer among women in Rwanda.

Rwandacancer du col de l'utérusAfrica CDCdocument of 52 observations

50 %La prévalence de la neuropathie chez les personnes vivant avec le VIH au Rwanda était de 50 % en 2014.

RwandaVIH/sidaobserved 2014HAL · Unilimdocument of 747 observations

6,269 dosesAs of 27 January 2025, Rwanda had administered 6,269 mpox vaccine doses, with 4,624 first doses and 1,655 second doses.

Rwandampoxobserved 27 January 2025Africa CDCdocument of 72 observations

3 countriesAs of the end of February 2025, three countries in the active phase — Burundi, Rwanda, and Central African Republic — were observing a declining trend in mpox cases.

Burundi · Rwandampoxobserved end of February 2025Africa CDCdocument of 110 observations

The R561H Pfk13 artemisinin resistance-associated mutation was recently identified in Tanzania, Uganda, and Rwanda.

Ouganda · Rwanda · Tanzaniepaludismepublished 2021International journal for parasitology. Drugs and drug resistanceeurope_pmcdocument of 4 observations

54.1 %The required increase in sample size for parasite prevalence in the 2014–2015 Rwanda DHS was 54.1%.

Rwandapaludismeobserved 2014-2015published 2017Malaria journaleurope_pmcdocument of 4 observations

59 %La fréquence de la neuropathie chez les personnes vivant avec le VIH au Rwanda était de 59 % en 2014.

RwandaVIH/sidaobserved 2014HAL · Unilimdocument of 747 observations

98 %By 2018, HPV vaccination coverage among eligible girls in Rwanda was 98%.

Rwandainfection à HPVobserved 2018Africa CDCdocument of 51 observations

21.18 %Among 422 individuals affected by early-onset hearing impairment in Rwanda, 21.18% (n = 89/422) had hearing impairment linked to early childhood meningitis infection.

Rwandaméningite (non précisée)published 2025Geneseurope_pmcdocument of 9 observations

5 countries5 countries — DRC, Rwanda, Uganda, Central African Republic, and Nigeria — are currently vaccinating against mpox.

Nigeria · Ouganda · RDC · RwandampoxAfrica CDCdocument of 72 observations

90 %Rwanda achieved a vaccination coverage rate exceeding 90% by the end of the first year of its HPV vaccination program in 2011.

Rwandainfection à HPVAfrica CDCdocument of 51 observations